A Form 144 notice of proposed sale was filed on November 17, 2026, by Gary A. Lyons, through the Gary A Lyons Revocable Living Trust U/A DTD 06/08/2012, disclosing a planned sale of 15,000 common shares of Neurocrine Biosciences Inc.
Key Highlights
- Seller: Gary A Lyons Revocable Living Trust U/A DTD 06/08/2012, with Gary A. Lyons listed as a Director of Neurocrine Biosciences Inc.
- Shares proposed for sale: 15,000 shares of common stock, with an aggregate market value of $2,479,650.00 as stated in the filing.
- Source of shares: The securities were acquired on November 17, 2026, through the exercise of stock options granted by the issuer, with payment made in cash.
- Approximate sale date: November 17, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- 10b5-1 plan: The filing notes a plan adoption date of August 18, 2026, indicating the sale is intended to rely on Rule 10b5-1 under the Exchange Act.
- Shares outstanding: 101,218,643 shares of common stock were reported as outstanding at the time of the filing.
- Prior sales: The filing reports nothing to report for securities sold during the past three months.
Neurocrine Biosciences Director Files Proposed Sale Notice Under Rule 144
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission on November 17, 2026, the Gary A Lyons Revocable Living Trust U/A DTD 06/08/2012 proposed to sell 15,000 shares of common stock in Neurocrine Biosciences Inc. (NASDAQ:NBIX), listed on NASDAQ. Gary A. Lyons is identified in the filing as a Director of the issuer, whose address is listed as 6027 Edgewood Bend Court, San Diego, California 92130.
The filing discloses that the 15,000 shares were acquired on November 17, 2026, through the exercise of stock options from the issuer, with cash payment made on the same date. The aggregate market value of the shares proposed to be sold is reported as $2,479,650.00. The intended broker for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services in New York.
The filing further indicates that the proposed sale is being made in reliance on a written trading plan adopted under Rule 10b5-1 of the Exchange Act, with a plan adoption date of August 18, 2026. The person signing the notice, Gary A. Lyons, represents by signature that he does not know any material adverse information regarding the current and prospective operations of the issuer that has not been publicly disclosed, as of the plan adoption date.
What Was Disclosed
A Form 144 notice was filed on November 17, 2026, disclosing a proposed sale of 15,000 Neurocrine Biosciences common shares, valued at $2,479,650.00, by a director's revocable living trust, with shares acquired via stock option exercise and sale intended under a Rule 10b5-1 plan.




Please wait processing your request...